MasterControl's GxP Lifeline - February 2009 Edition

February 2009

Video:

Trouble-Free Validation!

Feature Article:

FDA Expert Martin Browning on Outsourcing

For Pharmaceuticals and Biotechnology:

Three Steps to Improved Compliance Management

For Medical Device:

GCP Compliance Strategies for 2009

For Blood & Biologics:

Blood Bank ISBT 128 Implementation - A View from the Trenches

Did You Know?

Did you know that the European recast of the Medical Device Directives has been put on hold but the revision of the directives and new approach revision are coming?


Upcoming Events

Glossary

Submissions

Editorial Staff

About MasterControl















center

FDA Expert Martin Browning on Outsourcing

Everything can be outsourced - except responsibility. That's a rule the U.S. FDA lives by, and one you should embed in your policies, SOPs, and corporate culture.

Last year, the deaths associated with contaminated heparin - followed by the ensuing FDA investigations and embarrassing (and expensive) product recalls - underscored the importance of ensuring your suppliers comply with the regulations and conform to your manufacturing specifications at all times.


For Pharmaceuticals and Biotechnology: Three Steps to Improved Compliance Management

It's not surprising that pharmaceutical leaders have compliance concerns. If the $875 million fine leveled against TAP Pharmaceuticals back in 2001 didn't open eyes, the public's declining opinion of the drug industry - along with regular headlines about lawsuits, safety problems and generics squabbles - provide regular wake-up calls.


For Medical Device: GCP Compliance Strategies for 2009

On September 30, 2008 the FDA website listed 44 warning letters for the Bioresearch Monitoring (Bimo) Program's GCP inspection programs. These include inspections of clinical investigators, sponsors/CROs, and institutional review boards (IRBs). The federal fiscal year ends on September 30 and FDA maintains warning letters on their website for one year. A review of these warning letters sheds light on three new developments.


For Blood & Biologics: Blood Bank ISBT 128 Implementation - A View from the Trenches

David Linnemeyer's own blood bank's ISBT implementation was not quick or easy. How would he improve the process if he could? A review of his "own mishaps," according to Linnemeyer, will help you plan your own ISBT implementation more effectively.


Did You Know?

Did you know that the European recast of the Medical Device Directives has been put on hold but that the revision of the directives and new approach revision are coming?



If you would like to subscribe to GxP Lifeline, forward it to a colleague or unsubscribe, please click here.

Return to Top